Penserra Capital Management’s Zentalis Pharmaceuticals ZNTL Stock Holding History

Penserra Capital Management’s Portfolio ZNTL Stock Details ZNTL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-1,030	Closed	-$68K	–	1577
2021 Q3	$68K	Buy	1,030 +90	+10%	+$5.19K	﹤0.01%	959
2021 Q2	$50K	Buy	940 +25	+3%	+$1.34K	﹤0.01%	998
2021 Q1	$39K	Sell	915 -15	-2%	-$646	﹤0.01%	858
2020 Q4	$48K	Buy	+930	New	+$41.9K	﹤0.01%	694

Other funds holding ZNTL

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

MCMC

Matrix Capital Management Company Portsmouth, New Hampshire $46.3M AUM 114.38% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

APM

Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return

TCM

Tybourne Capital Management Hong Kong $30.9M AUM 20.1% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Penserra Capital Management's ZNTL Position: Q4 2021 in Review

Penserra Capital Management sold out of Zentalis Pharmaceuticals (ZNTL) in Q4 2021, closing a stake of 1,030 shares — an estimated $68K sold.

Penserra Capital Management first reported a position in ZNTL in Q4 2020 and held it in 4 quarters. The position peaked at $68K in Q3 2021. 139 funds tracked by Wall St. Rank hold ZNTL as of Q4 2021.

Penserra Capital Management reported no remaining Zentalis Pharmaceuticals position as of Q4 2021 after selling out during the quarter.
Penserra Capital Management sold 1,030 Zentalis Pharmaceuticals shares in Q4 2021, an estimated $68K.
Penserra Capital Management first reported a position in Zentalis Pharmaceuticals in Q4 2020 and held it in 4 quarters.
Penserra Capital Management's Zentalis Pharmaceuticals position peaked at $68K in Q3 2021.
139 funds tracked by Wall St. Rank held Zentalis Pharmaceuticals as of Q4 2021.

Based on Penserra Capital Management's 13F filing for Q4 2021, filed 15 Feb 2022.